Skip to main content

Table 2 IVT-AFL injections and visits over 12 and 24 months of treatment

From: Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW

 

Overall population (FAS; n = 514)

Regular cohort (n = 102)

Irregular cohort with initial doses (n = 268)

Irregular cohort without initial doses (n = 60)

IVT-AFL injections

 Mean (SD) over 12 Months

6.0 (2.1)

7.2 (0.8)

6.1 (2.2)

5.2 (1.8)

  Mean (SD) over 24 Months

8.8 (4.3)

10.6 (2.8)

9.3 (4.6)

7.8 (3.7)

  Min; max

1.0; 23.0

6.0; 17.0

3.0; 23.0

1.0; 16.0

  Median

8.0

11.0

9.0

8.0

  Q1; Q3

5.0; 12.0

8.0; 13.0

5.0; 12.0

4.0; 11.0

Visits

 Mean (SD) over 12 Months

9.3 (2.3)

9.5 (1.8)

10.1 (1.9)

8.8 (1.8)

 Mean (SD) over 24 Months

15.1 (5.1)

15.9 (4.2)

16.8 (4.2)

14.8 (3.8)

  Min; max

2.0; 29.0

8.0; 27.0

6.0; 29.0

6.0; 23.0

  Median

15.0

16.0

17.0

15.0

  Q1; Q3

12.0; 19.0

13.0; 19.0

14.0; 20.0

12.0; 17.0

  1. FAS full analysis set, IVT-AFL intravitreal aflibercept, n n numbers from the overall FAS population, Q1;Q3, interquartile range, SD standard deviation